 |
BioWorld-International-2003-03-19
For $55M, OSI Gets Novantrone U.S. Cancer Rights From Serono
For $55M, OSI Gets Novantrone U.S. Cancer Rights From Serono
Serono SA signed a licensing agreement with OSI Pharmaceuticals Inc., granting OSI exclusive rights to market and promote Novantrone in the U.S. in its approved oncology indications. (BioWorld International)